Dainippon Sumitomo Pharma America Announces Fda Acceptance Of Lurasidone New Drug Application For Treatment Of Schizophrenia Source: The Asahi Shimbun Thursday 11th March, 2010
- The NDA Included More Than 40 Clinical Studies in Schizophrenia, Involving 2,500 Patients Treated with Lurasidone - Fort Lee, N.J., March 10 - Dainippon Sumitomo Pharma America, Inc.